Your browser doesn't support javascript.
loading
Consensus and controversies in the definition, assessment, treatment and monitoring of BTcP: results of a Delphi study
Boceta, J; Torre, A de la; Samper, D; Farto, M; Sánchez-de la Rosa, R.
Affiliation
  • Boceta, J; Hospital Universitario Virgen de la Macarena. Servicio de Medicina Interna. Unidad de Hospitalización Domiciliaria y Cuidados Paliativos. Seville. Spain
  • Torre, A de la; Hospital Universitario Puerta del Hierro. Servicio de Oncología Radioterápica. Majadahonda. Spain
  • Samper, D; Hospital Germans Trias i Pujol. Clínica del Dolor. Servicio de Anestesiología. Badalona. Spain
  • Farto, M; TEVA Pharma. Medical Department. Madrid. Spain
  • Sánchez-de la Rosa, R; TEVA Pharma. Medical Department. Madrid. Spain
Clin. transl. oncol. (Print) ; 18(11): 1088-1097, nov. 2016. tab, graf
Article in English | IBECS | ID: ibc-156874
Responsible library: ES1.1
Localization: BNCS
ABSTRACT
Introduction. There is no unanimous consensus on the clinical features to define breakthrough cancer pain (BTcP). The current project aimed to investigate the opinion of a panel of experts on cancer pain on how to define, diagnose, assess, treat and monitor BTcP. Materials and methods. A two-round Spanish multi-centre exploratory Delphi study was conducted with medical experts (n = 90) previously selected from Medical Oncology Services, Radiation Oncology, Palliative Care/Home Care Teams, and Pain Units. The study intended to seek experts’ consensus and to define a set of recommendations for the management of BTcP. Results. It was generally agreed that, definition of BTcP implies that baseline pain should be controlled (84 %), although not necessarily with opioids (only 30 %); there must be exacerbations (98.9 %); the duration of each episode should last < 1 h (70 %); the intensity of pain ≥7 out of 10 (67.8 %); and the number of flares per day should not be less than four. All participants supported the use of the Davies algorithm for the diagnosis. The use of a ‘Patient Diary’ was highly recommended. The optimal treatment should have a rapid onset, a short-acting analgesic effect (1-2 h) and transmucosal nasal or oral administration. It was considered very important to develop protocols for the management of cancer pain. Conclusions. The present Delphi study identified a set of recommendations to define, assess and monitor BTcP (AU)
RESUMEN
No disponible
Subject(s)

Full text: Available Collection: National databases / Spain Database: IBECS Main subject: Quality of Life / Pain Measurement / Consensus Development Conferences as Topic / Delphi Technique / Pain Management Type of study: Practice guideline Aspects: Patient-preference Limits: Female / Humans / Male Language: English Journal: Clin. transl. oncol. (Print) Year: 2016 Document type: Article Institution/Affiliation country: Hospital Germans Trias i Pujol/Spain / Hospital Universitario Puerta del Hierro/Spain / Hospital Universitario Virgen de la Macarena/Spain / TEVA Pharma/Spain

Full text: Available Collection: National databases / Spain Database: IBECS Main subject: Quality of Life / Pain Measurement / Consensus Development Conferences as Topic / Delphi Technique / Pain Management Type of study: Practice guideline Aspects: Patient-preference Limits: Female / Humans / Male Language: English Journal: Clin. transl. oncol. (Print) Year: 2016 Document type: Article Institution/Affiliation country: Hospital Germans Trias i Pujol/Spain / Hospital Universitario Puerta del Hierro/Spain / Hospital Universitario Virgen de la Macarena/Spain / TEVA Pharma/Spain
...